Participants Exposed to OACs vs Participants Unexposed to OACs: Number of Participants With Atleast One Visit to Nursing Home in Non-valvular AF Participants Exposed to OAC and Unexposed to OAC
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0333 | 0.0328 | 0.0338 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0948 | 0.0938 | 0.0958 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.0615 | -0.0626 | -0.0604 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.351 | 0.345 | 0.358 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.329 | 0.323 | 0.335 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Participants Exposed to OACs than on Participants Unexposed to OACs | 16.3 | 16 | 16.6 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Participants Exposed to OACs | Participants with AF who were exposed to VKA or DOACs (including apixaban, rivaroxaban or dabigatran) within 30 days after inclusion and were identified from SNDS databases between 01-Jan-2016 and 31-Dec-2019 were included. | 16,170 | 485,646 | OG000 | ClinicalTrials.gov |
| Group 2 | Participants Unexposed to OACs | Participants with AF who were unexposed to OACs within 30 days after inclusion and were identified from SNDS between 01-Jan-2016 and 31-Dec-2019 were included. | 31,493 | 332,236 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | PRIMARY | ClinicalTrials.gov |
| Title | Number of Participants With Atleast One Visit to Nursing Home in Non-valvular AF Participants Exposed to OAC and Unexposed to OAC | ClinicalTrials.gov |
| Description | Participant was considered to have at least one visit to nursing home if the participant had at least one reimbursement corresponding to a nursing home on or in the 2 years prior to the index date. Index date was the date of the first dispensation of OAC for participants exposed to OAC and for participants unexposed to OAC, index date was the date of inclusion in the study. | ClinicalTrials.gov |
| Time frame | Up to 2 years prior to index date (index date was anytime in between 01-Jan-2016 and 31-Dec-2019); retrospective data was retrieved and analyzed during approximately 9 months of this observational study | ClinicalTrials.gov |
| Population | Certain AF incident population included participants with a first AF diagnosis date during study period but without history of OACs delivery in the 24 months before inclusion date, with no reported events of interest (stroke, major bleeding) between inclusion and index date. Here, ''Overall number of participants analyzed'' signifies participants evaluable for this outcome measure. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France | ClinicalTrials.gov |
| NCT number | NCT05838664 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | Atrial Fibrillation | ClinicalTrials.gov |
| Interventions | No OAC, VKA, apixaban, rivaroxaban, dabigatran | ClinicalTrials.gov |
| Lead sponsor | Pfizer | ClinicalTrials.gov |
| Results first posted | 2025-12-24 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT05838664?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.